Prognostic value of changes in high-sensitivity cardiac troponin T beyond biological variation in stable outpatients with cardiovascular disease: a validation study.


Journal

Clinical research in cardiology : official journal of the German Cardiac Society
ISSN: 1861-0692
Titre abrégé: Clin Res Cardiol
Pays: Germany
ID NLM: 101264123

Informations de publication

Date de publication:
Mar 2022
Historique:
received: 26 06 2021
accepted: 13 10 2021
pubmed: 26 10 2021
medline: 5 3 2022
entrez: 25 10 2021
Statut: ppublish

Résumé

To evaluate the prognostic implications of longitudinal long-term changes beyond the biological variation of high-sensitivity cardiac troponin T (hs-cTnT) in outpatients with stable or asymptomatic cardiovascular disease (CV) and to assess possible differences in the prognostic value while using reference change value (RCV) and minimal important differences (MID) as metric for biological variation. Hs-cTnT was measured at index visit and after 12 months in outpatients presenting for routine follow-up. The prognostic relevance of a concentration change of hs-cTnT values exceeding the biological variation defined by RCV and MID of a healthy population within the next 12 months following the stable initial period was determined regarding three endpoints: all-cause mortality (EP1), a composite of all-cause mortality, non-fatal myocardial infarction and stroke (EP2), and a composite of all-cause mortality, non-fatal myocardial infarction, stroke, hospitalization for acute coronary syndrome (ACS) or decompensated heart failure, and planned and unplanned percutaneous coronary interventions (PCI, EP3). Change in hs-cTnT values exceeding the biovariability defined by MID but not by RCV discriminated a group with a higher cardiovascular risk profile. Changes within MID were associated with uneventful course (NPV 91.6-99.7%) while changes exceeding MID were associated with a higher occurrence of all endpoints within the next 365 days indicating a 5.5-fold increased risk for EP 1 (p = 0.041) a 2.4-fold increased risk for EP 2 (p = 0.049) and a 1.9-fold increased risk for EP 3 (p < 0.0001). In stable outpatients MID calculated from hs-cTnT changes measured 365 ± 120 days apart are helpful to predict an uneventful clinical course. NCT01954303.

Identifiants

pubmed: 34694435
doi: 10.1007/s00392-021-01952-6
pii: 10.1007/s00392-021-01952-6
pmc: PMC8873128
doi:

Substances chimiques

Biomarkers 0
Troponin T 0

Banques de données

ClinicalTrials.gov
['NCT01954303']

Types de publication

Journal Article Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

333-342

Informations de copyright

© 2021. The Author(s).

Références

Clin Res Cardiol. 2011 Dec;100(12):1077-85
pubmed: 21792561
Clin Chem. 2016 Apr;62(4):631-8
pubmed: 26847217
Heart. 2012 Dec;98(24):1778-86
pubmed: 23118345
Circulation. 2018 Nov 13;138(20):e618-e651
pubmed: 30571511
Circulation. 2011 Apr 5;123(13):1367-76
pubmed: 21422391
JAMA. 2010 Dec 8;304(22):2494-502
pubmed: 21078811
N Engl J Med. 2009 Dec 24;361(26):2538-47
pubmed: 19940289
Coron Artery Dis. 2017 Dec;28(8):636-641
pubmed: 28914638
Clin Chem. 2012 Nov;58(11):1599-600
pubmed: 22968106
Nat Rev Cardiol. 2013 Nov;10(11):623-34
pubmed: 23979214
Stroke. 2013 Jul;44(7):2064-89
pubmed: 23652265
Clin Chem. 2011 Sep;57(9):1318-26
pubmed: 21771945
JAMA Intern Med. 2013 May 13;173(9):763-9
pubmed: 23568589
Atherosclerosis. 2016 Sep;252:207-274
pubmed: 27664503
J Am Coll Cardiol. 2017 Jul 4;70(1):1-25
pubmed: 28527533
N Engl J Med. 2015 Aug 13;373(7):610-20
pubmed: 26267622
Eur Heart J Acute Cardiovasc Care. 2016 Oct;5(6):409-418
pubmed: 26450785
Clin Chem. 2010 Feb;56(2):254-61
pubmed: 19959623
Eur Heart J. 2011 Feb;32(4):404-11
pubmed: 21169615
Eur Heart J. 2021 Apr 7;42(14):1289-1367
pubmed: 32860058
Eur Heart J. 2020 Jan 14;41(3):407-477
pubmed: 31504439
JAMA. 2010 Dec 8;304(22):2503-12
pubmed: 21139111
Curr Med Res Opin. 2009 May;25(5):1171-8
pubmed: 19323611
Clin Biochem. 2019 May;67:7-11
pubmed: 30872042

Auteurs

Moritz Biener (M)

Zentrum für Innere Medizin, Klinik für Kardiologie, Angiologie und Pneumologie, Universitätsklinikum Heidelberg, Heidelberg, Germany.

Evangelos Giannitsis (E)

Zentrum für Innere Medizin, Klinik für Kardiologie, Angiologie und Pneumologie, Universitätsklinikum Heidelberg, Heidelberg, Germany. evangelos_giannitsis@med.uni-heidelberg.de.

Katharina Hogrefe (K)

Zentrum für Innere Medizin, Klinik für Kardiologie, Angiologie und Pneumologie, Universitätsklinikum Heidelberg, Heidelberg, Germany.

Matthias Mueller-Hennessen (M)

Zentrum für Innere Medizin, Klinik für Kardiologie, Angiologie und Pneumologie, Universitätsklinikum Heidelberg, Heidelberg, Germany.

Hanna Fröhlich (H)

Zentrum für Innere Medizin, Klinik für Kardiologie, Angiologie und Pneumologie, Universitätsklinikum Heidelberg, Heidelberg, Germany.

Hugo A Katus (HA)

Zentrum für Innere Medizin, Klinik für Kardiologie, Angiologie und Pneumologie, Universitätsklinikum Heidelberg, Heidelberg, Germany.

Norbert Frey (N)

Zentrum für Innere Medizin, Klinik für Kardiologie, Angiologie und Pneumologie, Universitätsklinikum Heidelberg, Heidelberg, Germany.

Lutz Frankenstein (L)

Zentrum für Innere Medizin, Klinik für Kardiologie, Angiologie und Pneumologie, Universitätsklinikum Heidelberg, Heidelberg, Germany.

Tobias Täger (T)

Zentrum für Innere Medizin, Klinik für Kardiologie, Angiologie und Pneumologie, Universitätsklinikum Heidelberg, Heidelberg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH